The European Society for Medical Oncology (ESMO) has launched a new Clinical Trials Funding Initiative, committing €1 million to support independent academic clinical research aimed at optimising cancer care, reducing treatment burden and improving patient outcomes worldwide.
Announced on September 10, 2026, the programme will support pragmatic interventional studies with international relevance, particularly research addressing questions that may have major implications for patients and healthcare systems but are often not priorities for commercially sponsored trials.
Optimising Existing Cancer Treatments
Rather than focusing primarily on developing new anticancer medicines, the initiative is designed to investigate how existing treatments and care pathways can be used more effectively and efficiently.
Research areas may include treatment duration, treatment sequencing, treatment de-escalation, streamlined treatment delivery and alternative models of care. The overall objective is to reduce unnecessary treatment and its associated toxicity and burden while maintaining clinical effectiveness and improving access to optimal cancer care.
The initiative will also support research addressing patient-centred care and the sustainability of healthcare systems.
Fabrice André, MD, PhD, ESMO President, highlighted the global-access implications of the initiative in a LinkedIn post:
“ESMO launches an initiative to fund academic clinical trials. The funding will be used to expand existing trials in new areas of the world. The trials will be selected to reduce treatment burden while keeping efficacy, and thereby opening access to optimal care to more patients.”
In ESMO’s official announcement, André also emphasized that many clinically important questions concern the optimisation of existing treatments and care pathways rather than the development of new drugs. He said the programme, which forms part of the ESMO Roadmap 2030, is intended to strengthen support for independent academic research addressing unmet needs in oncology.
ESMO – European Society for Medical Oncology/LinkedIn
Who Can Apply?
Eligible applicants include academic institutions, cancer centres, hospitals and cooperative research groups conducting interventional clinical trials aligned with the programme’s objectives.
Studies may already be recruiting, be approved but not yet recruiting, or be awaiting regulatory and institutional approvals when the application is submitted.
Applications will be evaluated according to factors including:
- scientific quality and feasibility;
- potential to change clinical practice;
- impact on patients;
- healthcare sustainability;
- international and global relevance.
Applicants are also expected to describe how patients have been involved in the study’s design and plans for dissemination, reinforcing the initiative’s focus on patient-centred clinical research.
Oncology Community Welcomes Focus on De-escalation
The announcement has drawn positive reactions from oncologists who have advocated for greater investment in treatment optimisation and de-escalation studies.
Bishal Gyawali, MD, PhD, FASCO, wrote on X:
“This is great news and fantastic leadership from ESMO. We need more treatment optimization de-escalation trials. These trials are patient-centric but won’t be funded by industry. So these funding opportunities through organizations like ESMO are incredibly important.”
Dario Trapani, MD, PhD, also welcomed the initiative, writing on X:
“So exciting to see this new initiative from ESMO! For all academic researchers, cooperative groups, and your ideas that are relevant to patients & cancer care, everywhere, this opportunity is UNMISSABLE!!”
Supporting Questions That Industry May Not Address
Independent academic trials can play a particularly important role in answering questions where there may be limited commercial incentive to conduct large prospective studies.
These include whether treatments can safely be given for shorter periods, at lower intensity or with fewer interventions; whether different sequencing strategies produce equivalent or better outcomes; and whether changes in treatment delivery can improve quality of life and access while preserving efficacy.
ESMO describes such independent academic research as an important component of improving both patient outcomes and the sustainability of cancer care. The organisation represents more than 50,000 oncology professionals worldwide.
The application deadline is November 1, 2026. Researchers can access the Call for Applications, Applicant Guidance Document, and Application Form through ESMO’s Clinical Trials Funding Initiative webpage.
Read further on OncoDaily: Antoni Ribas Receives 2026 ESMO Lifetime Achievement Award
